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Review Article
The Impact of Riluzole on Neurobehavioral
Outcomes in Preclinical Models of Traumatic
and Nontraumatic Spinal Cord Injury:
Results From a Systematic Review of
the Literature
Lindsay A. Tetreault, PhD1,2,3, Mary P. Zhu, BSc2,4, Jefferson R. Wilson, MD, PhD2,4,
Spyridon K. Karadimas, MD, PhD1,2, and Michael G. Fehlings, MD, PhD1,2
Abstract
Study Design: Systematic review.
Objective: To evaluate the impact of riluzole on neurobehavioral outcomes in preclinical models of nontraumatic and traumatic
spinal cord injury (SCI).
Methods: An extensive search of the literature was conducted in Medline, EMBASE, and Medline in Process. Studies were
included if they evaluated the impact of riluzole on neurobehavioral outcomes in preclinical models of nontraumatic and traumatic
SCI. Extensive data were extracted from relevant studies, including sample characteristics, injury model, outcomes assessed,
timing of evaluation, and main results. The SYRCLE checklist was used to assess various sources of bias.
Results: The search yielded a total of 3180 unique citations. A total of 16 studies were deemed relevant and were summarized in
this review. Sample sizes ranged from 14 to 90, and injury models included traumatic SCI (n ¼ 9), degenerative cervical mye-
lopathy (n ¼ 2), and spinal cord-ischemia (n ¼ 5). The most commonly assessed outcome measures were BBB (Basso, Beattie,
Besnahan) locomotor score and von Frey filament testing. In general, rats treated with riluzole exhibited significantly higher BBB
locomotor scores than controls. Furthermore, riluzole significantly increased withdrawal thresholds to innocuous stimuli and tail
flick latency following application of radiant heat stimuli. Finally, rats treated with riluzole achieved superior results on many
components of gait assessment.
Conclusion: In preclinical models of traumatic and nontraumatic SCI, riluzole significantly improves locomotor scores, gait
function, and neuropathic pain. This review provides the background information necessary to interpret the results of clinical
trials on the impact of riluzole in traumatic and nontraumatic SCI.
Keywords
riluzole, spinal cord injury, review, degenerative cervical myelopathy, locomotor scores, neuropathic pain
Introduction
Nontraumatic and traumatic injuries to the spinal cord initiate a
cascade of pathophysiological changes that may impair normal
motor, sensory, and autonomic functions and cause irreversible
tissue damage.1,2 Surgical intervention is recommended as the
preferred treatment strategy for patients with moderate to
severe degenerative cervical myelopathy (DCM) as it can halt
neurologic decline and significantly improve functional
impairment, disability, and quality of life.3,4 Furthermore, early
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surgical management of traumatic spinal cord injury (SCI) is
increasingly prioritized due to emerging evidence that patients
decompressed and stabilized within 24 hours of injury exhibit
superior outcomes.5,6
There is also an opportunity to explore adjuvant treatments
for the management of traumatic and nontraumatic SCI, includ-
ing pharmacological strategies. Compression of the spinal cord
alters its micro- and macro-vasculature, results in ischemia, and
disturbs ionic homeostasis through the activation of voltage-
gated sodium channels.7 An influx of sodium results in cellular
swelling, edema, and an increase in the activity of the sodium-
calcium exchanger on the neuronal cell membrane.8 Calcium
entry pre-synaptically triggers the release of glutamate, which
causes excitotoxicity and neuronal death. A neuroprotective
drug such as riluzole may be effective at halting this cascade
and preserving the structural integrity of the spinal cord.
Riluzole has neuroprotective, anti-ischemic, and anti-
epileptic properties as well as several proposed mechanisms
of action.9 Specifically, it is a sodium channel blocker, a reg-
ulator of glutamate release, an antagonist at both NMDA and
non-NMDA receptors, and an inhibitor of GABA reuptake.10-12
Randomized controlled trials have demonstrated that riluzole
increases survival, decreases the necessity for tracheostomy,
and attenuates muscle deterioration in patients with amyo-
trophic lateral sclerosis.13,14 Riluzole has also demonstrated
promising results in other neurological conditions, including
Huntington’s disease, cerebellar ataxia, and cervical SCI.15-18
Furthermore, in vitro studies have indicated that riluzole sig-
nificantly improves axonal conduction, prevents cellular necro-
sis and apoptosis, and enhances nerve fiber regeneration.19
Given its mechanism of action and the cellular changes that
follow compression of the spinal cord, there may be a role for
riluzole as an adjuvant therapy in the management of DCM and
SCI.
This systematic review aims to evaluate the impact of rilu-
zole on neurobehavioral outcomes in preclinical models of
nontraumatic and traumatic SCI. This review serves as an ini-
tial step in evaluating the suitability of riluzole for the manage-
ment of DCM and SCI.
Methods
Eligibility Criteria
Table 1 provides a detailed summary of the inclusion and
exclusion criteria for this review.
Population and Injury Model
This review targeted studies on animal models (eg, rats, mice,
rabbits, primates) of traumatic and nontraumatic SCI. Studies
were excluded if they consisted of humans or if the animal
model mimicked root avulsion or peripheral nerve injuries,
traumatic brain injury, epilepsy, Parkinson’s disease, or amyo-
trophic lateral sclerosis.
Intervention and Comparison
The intervention of interest was riluzole, injected intrave-
nously, intraperitoneally, intrathecally, or intracerebroventri-
cularly. There were no limitations on the dosing, timing of
administration, or duration of treatment. Studies were only
included if they had a control group (eg, vehicle injection) and
Table 1. Inclusion and Exclusion Criteria.
Inclusion Exclusion
Population Any Animal Model including
 Rats
 Rabbits
 Mice
 Primates
 Humans
Injury
models
 Traumatic spinal cord
injury
 Degenerative cervical
myelopathy
 Spinal cord ischemia
 Non-spinal
pathologies
 Root evulsion
injuries
 Peripheral nerve
injuries (eg, sciatic
nerve)
 Traumatic brain
injury
 Epilepsy
 Parkinson’s disease
 Amyotrophic
lateral sclerosis
Intervention  Riluzole delivered
intraperitoneally,
intrathecally,
intravenously, and/or
intracerebroventricularly
Not applicable
Comparison  Control, vehicle injection  Non-drug
treatments (eg,
hypothermia)
 Methylprednisolone
 Phenytoin
 Mexiletine
 Glibenclamide
 Other drug
preparations
Outcomes Neurobehavioral assessment
 BBB locomotor score
 Inclined board test
 von Frey filament test
 Beam balance
 Gait assessment
 Grip strength
Autonomic function or
physiological
parameters
 Bladder function
 Heart rate
 Rectal temperature
 Ptosis
In vitro assessment
 Oxidative damage
 Axonal or neuronal
preservation
 Microglial activation
 Blood flow
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specifically evaluated outcomes with respect to this group.
Studies were excluded if they only compared the efficacy of
riluzole to other treatments (eg, hypothermia) or drug regimens
(eg, methylprednisolone, phenytoin, glibenclamide,
mexiletine).
Outcomes
This review primarily focused on neurobehavioral outcomes
such as the Basso, Beattie, Besnahan (BBB) locomotor score,
the inclined board test, the von Frey filament test, beam bal-
ance, gait assessment, and grip strength. Studies were excluded
if they only discussed autonomic function or physiological
parameters (eg, bladder function, heart rate, blood pressure)
or if they evaluated in vitro changes (eg, oxidative damage,
microglial activation, axonal loss) following riluzole
administration.
Information Sources
A systematic search was conducted of MEDLINE, MEDLINE
In-Process, and EMBASE to identify relevant studies. The
search was completed on November 13, 2017.
Search Strategy
A search strategy was constructed with the assistance of a
librarian at the Toronto Western Hospital. The strategy was
originally prepared in MEDLINE and then appropriately mod-
ified for EMBASE. The terms used to search both databases are
provided in Appendix A, available online. Only studies involv-
ing animal models of spinal pathologies and in English were
considered for inclusion, with no other limits applied.
Study Selection
Duplicates, conference proceedings, editorials, and reviews
were first excluded in Endnote. The remaining abstracts were
reviewed independently by 2 of the authors and sorted based on
predefined inclusion criteria (MZ and LT). In some cases, full
text investigation was required to clarify whether the study was
relevant. Discussion was used to resolve disagreement between
reviewers.
Data Extraction and Synthesis
The following data were extracted from each article: author,
year and location of investigation; sample characteristics,
including sample size, type and weight of animals, and level
of injury; injury model; intervention, including dose and route
of drug administration; outcomes evaluated and timing of
assessment; and statistical methods. Main study conclusions
were also extracted if they highlighted the impact of riluzole
on neurobehavioral outcomes compared to controls.
Assessment of Risk of Bias and Study Quality
The risk of bias of each study was evaluated using the SYRCLE
tool (Systematic Review Center for Laboratory Animal Experi-
mentation).20 This checklist, presented in Table 2, was adopted
from the Cochrane Collaboration risk of bias tool and modified
to encompass certain biases that are relevant to animal experi-
ments. It consists of 10 domains related to 6 types of bias:
selection, performance, detection, attrition, reporting, and other
biases.20 Signaling questions provided by Hooijmans et al were
used to assist in judging whether the experiment had a low,
moderate, or high risk of bias for each entry.20 The authors of
this study also recommended not to compute a summary score
as that would involve assigning weights to each domain.
Reporting
This review was formatted using the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
checklist.21
Results
Study Selection
The search yielded a total of 3180 unique citations. Using End-
note, 1799 articles were excluded because they were either not
in English (n ¼ 196) or were conference proceedings, editor-
ials, literature reviews, or commentaries (n ¼ 1603). After
review of the remaining titles and abstracts, 1340 studies did
not meet the inclusion criteria. Following full text investiga-
tion, an additional 25 studies were excluded; reasons for
Table 2. Systematic Review Center for Laboratory Animal
Experimentation (SYRCLE) Toola.
Questions
Type of Bias
Addressed
Was the allocation sequence adequately generated
and applied?
Selection bias
Were the groups similar at baseline or was there
adjustment for confounders in the analysis?
Selection bias
Was the allocation adequately concealed? Selection bias
Were the animals randomly housed during the
experiment?
Performance bias
Were the caregivers and/or investigators blinded
from which intervention each animal received
during the experiment?
Performance bias
Were animals selected at random for outcome
assessment?
Detection bias
Was the outcome assessor blinded? Detection bias
Were incomplete outcome data adequately
addressed?
Attrition bias
Are reports of the study free of selective outcome
reporting?
Reporting bias
Was the study apparently free of other problems
that could results in high risk of bias?
Other
aDerived from Hooijmans et al.20
Tetreault et al 3
exclusion are provided in Appendix B. A total of 16 studies
were considered relevant following this review process
(Figure 1).
Study Characteristics
Sixteen studies evaluated the impact of riluzole on neurobeha-
vioral outcomes in either rat (n ¼ 14)9,10,12,19,22-31 or rabbit
(n ¼ 2)11,32 models of spinal cord pathology. Injury models
included acute SCI via weight dropping, micro-scissors, or
vascular clips (n ¼ 9)9,12,19,22,24,27-30; DCM through progres-
sive compression of the cord (n ¼ 2)26,33; and spinal cord
ischemia via occlusion of the aorta (n ¼ 5).10,11,25,31,32 Of the
models of acute SCI, 4 were at the thoracic level, 3 were
cervical, 2 were cervicothoracic (C7-T1), and 1 was sacral. The
most commonly assessed outcome measures were BBB loco-
motor score (n ¼ 7) and gait analysis (n ¼ 4). Table 3 sum-
marizes the tools used to evaluate outcomes. Table 4 provides
an overview of the included studies.
Risk of Bias
The SYRCLE tool evaluated risk of bias across studies. In the
majority of studies, allocation sequence was adequately gener-
ated, applied (n ¼ 16), and concealed (n ¼ 15). Fifteen studies
randomly selected animals for outcome assessment. Investiga-
tors were blinded from the intervention in 6 studies and out-
come assessors were blinded in 11 studies. Animals were
randomly housed during the experiment in only 6 studies and
incomplete outcome data was only addressed in 3 studies.
Finally, it was unclear whether outcomes were selectively
reported in any of the studies (Appendix C).
What Is the Impact of Riluzole on Neurobehavioral
Outcomes?
The main results are summarized in Table 5.
Basso, Beattie, Besnahan Locomotor Score. Six studies evaluated
the impact of riluzole on BBB locomotor scores in rats with
SCI.12,19,22,27,29,30 In a study by Hosier et al, rats treated with
riluzole exhibited significantly higher BBB scores than con-
trols in both the ipsilateral and contralateral limbs at 6 weeks
following injury.22 Vasconcelos et al also demonstrated
improved BBB scores in a riluzole group at 1 and 2 weeks
postinjury, but not at 3 or 4 weeks.30 Furthermore, only rats
in the riluzole group were able to achieve plantar weight sup-
port at 3 weeks. In a third study, rats treated with 8 mg/kg
riluzole intraperitoneally at 1 and 3 hours after injury exhibited
significant improvements in BBB score compared to controls at
2 to 6 weeks following injury.19 However, only rats adminis-
tered with riluzole 1 hour after injury demonstrated significant
improvement on the BBB subscores. In contrast, 3 studies indi-
cated no association between BBB score and riluzole adminis-
tration in preclinical models of SCI.12,27,29
A single study by Wu et al examined BBB score and sub-
scores in rats treated with riluzole 4 hours after occlusion of the
aorta.31 Based on their results, riluzole preserved function at 1
and 5 days following ischemia. Furthermore, rats treated with
riluzole had significantly higher stepping and coordination sub-
scores than controls.
Von Frey Filament. Four studies assessed sensitivity to innoc-
uous mechanical stimulation using von Frey filament test-
ing.12,19,26,33 In a study by Haman and Sagen, riluzole
administered intraperitoneally significantly increased with-
drawal thresholds at 60, 90, and 120 minutes posttreat-
ment.12 Furthermore, intracerebroventricular injection of
riluzole increased withdrawal thresholds in a dose-
dependent manner.12 In contrast, lower doses of intraperito-
neal riluzole (0.8 or 2.5 mg/kg) or riluzole administered
intrathecally did not affect the response to mechanical sti-
muli. A second study by Moon et al also demonstrated
increased withdrawal thresholds in both paws in rats treated
intraperitoneally with riluzole.26 Furthermore, a combina-
tion of decompression surgery and riluzole was superior at
attenuating mechanical allodynia as compared to decom-
pression alone.33 Finally a study by Wu et al failed to iden-
tify significant differences in response to mechanical stimuli
between rats injected with riluzole and controls.19
Tail Flick. Three studies assessed thermal hyperalgesia using the
tail flick test.12,26,33 Intraperitoneal injection of riluzole signif-
icantly increased tail flick latency compared with controls.12,26
Furthermore, rats receiving a combination of surgical decom-
pression and riluzole had significantly reduced thermal
Figure 1. Overview of Study Selection.
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allodynia compared with decompression alone.33 There were,
however, no significant changes in latencies between controls
and rats receiving intrathecal or intracerebroventricular
riluzole.12
Tarlov Score. Three studies evaluated the impact of riluzole on
Tarlov scores.10,11,32 Based on their results, rats receiving
riluzole exhibited significantly improved Tarlov scores com-
pared with controls. Furthermore, the incidence of complete
paraplegia, defined as a Tarlov score of 0, was significantly
lower in rats treated with riluzole.11 In contrast, the incidence
of paraparesis, defined as a Tarlov score of 1, 2, or 3, was not
significantly different between riluzole and control groups.11
Furthermore, results from the study by Lang-Lazdunski et al
Table 3. An Overview of the Tools Used to Evaluate Outcomes.
Scales Summary of Tool
Basso, Beattie, Besnahan Locomotor
score12,19,22,27,29–31
Assesses hindpaw movement and weight bearing, coordination of the hindlimb with the forelimbs, and
placement of trunk and tail. Scores range from 0 to 21, where 0 is a complete lack of hindlimb
movement and 21 is normal function.
Angle Board Test/Inclined
plane9,22,29
Maximum angle at which an animal can support its weight on an inclined plane (up- and/or down-angled)
for 5 seconds; measured from 0 to 90.
von Frey filament test12,19,26 Assesses sensitivity to innocuous mechanical stimulation. A von Frey filament is applied to the skin of the
hindpaw or forepaw and a withdrawal reaction is observed. If no reaction is elicited, then a higher force
filament is used. The smallest filament that elicits a response is considered the threshold stimulus.
Tail flick test12,26 Assesses thermal hyperalgesia. A circle of light is applied to the dorsal tail. The tail flick withdrawal latency
is the time between application of the radiant heat stimulus and withdrawal of the tail from the light.
Beam Balance22 0, falls off; 1, hangs on; 2, stands on beam but one or two legs slip off; 3, stands on beam; 4, walks on beam.
Accelerating rotarod22 Accelerating rod, starting at 4 rpm and increasing at a rate of 2 rpm every 5 seconds to a maximum of
45 rpm.
Gait analysis19,26,28,33 Swing phase duration, swing speed, paw intensity, paw print width, paw print length, stride length, stance
phase, 4-limb support, print positions, forepaw initial contact.
Grip strength28 Animals are allowed to grasp a bar. They are then pulled away parallel to the degree they grasped at until
they release the bar. Grip force is measured.
Tarlov scale10,11,32 0, no movement; 1, slight movement; 2, sits with assistance; 3, sits alone; 4, weak hop; 5, normal hop OR
0, paraplegic with no lower extremity function; 1, poor lower extremity function, weak antigravity
movement only; 2, some lower extremity motor function with good antigravity strength but inability to
draw legs under body or hop; 3, ability to draw legs under body and hop but not normally; 4, normal
motor function.
Paw placement test28 Forelimb activity during exploration in a cylinder. The number of times the animals places its ipsilateral or
contralateral forelimb or both is recorded.
Swimming test30 Animal swimming velocity is recorded in a circular pool over a duration of 2 minutes.
Activity box test30 Assesses motor behavior by calculating total distance traveled in 5 minutes.
Gridwalk analysis19 Assesses sensory-motor coordination of the limbs. Requires accurate paw placement and substantial
motor control to cross a meter-long runaway of round metal bars. Spaced unevenly to avoid
habituation. Number of footfalls are recorded.
Response to non-noxious tactile
stimulation22
0, dead; 1, alive, but no response; 2, weak response (moves head); 3, strong response (moves head, neck
and forelimbs).
Response to quick stretch and pinch
stimuli24
0, minimal (45 flexion) response to stimulus; 1, 50 to 90 flexion; 2, >90 to 180 flexion; 3, >180 to
225 flexion; 4, >225 to 360 flexion; 5, significant coiling of the tail and/or activation of the flexors,
extensors and abductors lasting >2 seconds.
Response to light touch22 0, no response; 1, minimal flexion of the tail away from the stimulus; 2, pronounced flexing of the tail away
from the stimulus.
Motor function score, modified from
Gale et al9
The animals were observed in an open field for at least 1 minute; 0, no movement of the hindlimbs; 1,
barely perceptible movement of hindlimbs; 2, brisk movements at most hindlimb joints in one or both
limbs but no coordination or weight support; 3, alternative stepping and propulsive movements of
hindlimbs but no weight support; 4, can support weight on hindlimbs; 5, walks with only mild deficit; 6,
normal walking.
Motor scores22,25 0, no movement of hindlimbs, no weight bearing; 1, barely perceptible movements of hindlimbs, no weight
bearing; 2, frequent and/or vigorous movement of hindlimbs but no weight support; 3, alternative
stepping and propulsive movements of hindlimbs, some intermittent weight bearing; 4, can support
weight and walk with deficit apparent; 5, normal walking.
Motor sensory deficit index
(MSDI)25
Walking with lower extremities: 0, normal; 1, toes flat under body when walking but ataxia is present; 2,
knuckle walking; 3, movements in lower extremities but unable to knuckle walk; 4, no movement, drags
lower extremities. Pain sensation: 0, normal, withdrawal to toe pinch; 1, squeals to toe pinch but does
not withdraw; 2, no reaction to toe pinch. MSDI is a summation of walking with lower extremities and
pain sensation.
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Table 5. Statistical Analysis and Main Conclusions of Included Studies
Author (Year) Statistical Analysis Main Conclusions
Ates et al (2007)9  Kruskal-Wallis test
 Bonferroni Mann-
Whitney test
 Rats treated with riluzole exhibited greater improvements in motor function and angle
board scores compared to controls over the 6-week period (P < .05).
Hama and Sagen
(2011)12
 Two-way ANOVA with
repeated measures
 Newman-Keuls for post
hoc comparisons
 On von Frey filament testing, riluzole (8 mg/kg i.p.) significantly increased withdrawal
thresholds at 60 (P < .05 vs baseline), 90 and 120 (P < .05 vs baseline and vehicle) minutes
post-injection.
 Lower doses of riluzole (0.8 or 2.5 mg/kg i.p.) did not affect withdrawal thresholds.
 No significant changes in withdrawal threshold were observed following i.t. riluzole or
vehicle injection.
 Riluzole (1, 10, 30 mg i.c.v.) significantly increased withdrawal thresholds in a dose-
dependent manner (P < .05 vs baseline and vehicle at 30 minutes).
 Riluzole (8 mg/kg i.p.) significantly increased tail flick latency at 30 to 120 minutes post-
injection (P < .05 vs baseline and vehicle).
 No significant changes in latencies were observed following i.t. or i.c.v. injection of riluzole
or vehicle (P > .05).
 BBB locomotor scores for rats receiving riluzole or vehicle were not significantly different
than scores 4 weeks after SCI (P > .05).
Hosier et al
(2015)22
 Kruskal-Wallis test with
Dunn’s post hoc
comparison
 One-way ANOVA with
Fisher’s post hoc
comparisons
 There were no significant differences in arousal scores and motor scores between the
control and riluzole groups (P > .05, day 7 after trauma).
 Ipsilateral and contralateral modified BBB scores were significantly higher in rats receiving
riluzole than controls (P < .05, week 6 after trauma).
 Time on accelerating rotarod was significantly longer in rats receiving riluzole than
controls (P < .05, week 6 after trauma).
 There were no significant differences in inclined plane angle and beam balance scores
between the control and riluzole groups (P > .05, week 6 after trauma).
Karadimas et al
(2015)33
 One-way ANOVA with
Tukey post hoc
 A combination of surgical decompression and riluzole administration resulted in longer
forelimb stride length, higher regularity index and shorter forepaw initial contact than
decompression alone (P < .05, 1 week after surgery).
 Forelimb stance phase, percentage 4-limb support and print positions did not differ
between decompression only and decompression plus riluzole groups (P > .05, 1 week
after surgery).
 A combination of surgical decompression and riluzole administration resulted in a shorter
stance phase, longer stride length, stronger handgrip and decreased print positions than
decompression alone (P < .05, 12 weeks after surgery).
 On von Frey filament testing, a combination of surgical decompression and riluzole
significantly increased withdrawal thresholds in the hindpaw compared to decompression
only (P < .05, 12 weeks after surgery).
 Rats receiving a combination of surgical decompression and riluzole had significantly
increased tail withdrawal latency compared to rats treated with only decompression at
12 weeks (P < .05).
Kitzman (2009)24  Kruskal-Wallis test
 Dunn’s multiple
comparison tests
 Rats receiving riluzole 8mg/kg had a significantly decreased response to light touch
(1 hour but not 3, 6, and 12 hours post-injection) and pinch (1 and 3 hours but not 6 and
12 hours post-injection) compared to controls (P < .05).
 Rats receiving riluzole 10 mg/kg had a significantly decreased response to light touch,
stretch and pinch compared to controls at 1 and 3 hours but not 6 and 12 hours post-
injection (P < .05).
Lang-Lazdunski
et al (2000)25
 Kruskal-Wallis test
 Mann-Whitney U tests
 MSDI scores were significantly better in the riluzole group than in the control group at 24
(P ¼ .0001), 48 (P ¼ .0002), and 96 hours (P ¼ .009) after reperfusion
Lang-Lazdunski
et al (2000)32
 Kruskal-Wallis tests
 Mann-Whitney U tests
 Modified Tarlov scores were significantly better in the riluzole and the riluzole with
MgSO4 groups than in the MgSO4 only and control groups (P < .01).
(continued)
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Table 5. (continued)
Author (Year) Statistical Analysis Main Conclusions
Lang-Lazdunski
et al (1999)10
 Mann-Whitney U tests  Tarlov scores were significantly better in the riluzole group than in the control group,
regardless of dose and timing of administration (P < .001, 24 hours after ischemia).
 Rats receiving riluzole 4 mg/kg i.v. 30 minutes before ischemia and at the onset of
reperfusion achieved significantly better Tarlov scores than rats treated with riluzole
8 mg/kg i.v. only at the onset of reperfusion (P ¼ .00 444, 24 hours after ischemia).
 Tarlov scores did not significantly differ between rats treated with riluzole 8 mg/kg i.v.
30 minutes before ischemia and those receiving riluzole 4 mg/kg i.v. 30 minutes before
ischemia as well as at the onset of reperfusion (P ¼ .2004, 24 hours after ischemia).
Lips et al (2000)11  Fishers exact test  Rats receiving riluzole exhibited a significant decrease in the incidence of complete
paraplegia (48 and 72 hours) and improved Tarlov scores compared with controls
(P < .05).
 Incidence of paraparesis was not significantly different between riluzole and control
groups at any time point assessed (P > .05).
Moon et al
(2014)26
 One- or 2-way ANOVA
with Bonferroni
correction
 t Tests
 On von Frey filament testing, riluzole significantly increased withdrawal thresholds in both
the forepaw (2, 6, 7, and 8 weeks) and hindpaw (3 to 8 weeks) compared to the control
group (P < .05).
 Riluzole significantly increased tail withdrawal latency compared to the control group at 8
weeks (P < .05).
 Rats in the riluzole group had significantly shorter forelimb and hindlimb swing phases,
greater forepaw and hindpaw intensity, and faster hindlimb swing speed than the control
group at 8 weeks (P < .05).
Mu et al (2000)27  Two-way ANOVA
 Fishers test
 There were no significant differences in BBB open field locomotor scores between the
riluzole and control group at any assessment point (P > .05).
 Rats receiving a combined administration of riluzole and MP exhibited higher BBB open
field locomotor scores than controls at 4, 5, and 6 weeks (P < .05).
Satkunendrarajah
et al (2016)28
 One- or 2-way ANOVA
with Bonferroni
correction
 t Test
 Rats in the riluzole group had significantly increased ipsilateral forelimb grip strength (3 to
43 days post-surgery) and contralateral forelimb grip strength (23 to 43 days post-
surgery) compared to the control group (P < .01).
 Rats in the riluzole group had significantly faster swing speeds and longer ipsilateral stride
lengths compared to the control group at 2 (P < .005, P < .001) and 4 weeks (P < .05,
P < .008) post-surgery but not at 6 weeks.
 Rats in the riluzole group had significantly increased ipsilateral forepaw print width during
stance phase and longer ipsilateral forepaw print length (2, 4, and 6 weeks post-injury)
compared to the control group (P < .05). Print length and width of the contralateral
forepaw were not significantly different between groups.
 Rats in the riluzole group had a significantly higher percentage of ipsilateral paw
placements (2, 4, and 6 weeks post-injury) than the control group.
Schwartz and
Fehlings
(2001)29
 Two-factor ANOVA
 Student-Newman-Keuls
multiple range test
 Fishers test
 Rats treated with riluzole exhibited higher inclined plane scores than controls at 1, 2, 3, 4,
and 6 weeks following injury (P < .05).
 There were no significant differences in BBB locomotor scores between the riluzole and
the control group at any assessment point (P > .05).
Vasconcelos et al
(2016)30
 One-way or 2-way
ANOVA with post-hoc
Bonferroni test
 Rats treated with riluzole achieved significantly higher BBB sores than controls at 1 and 2
weeks post-injury (P < .05) but not at 3 and 4 weeks post-injury. There were no
differences in BBB scores between the control group and the combined riluzole and
MgSO4 group.
 Rats treated with riluzole traveled a significantly longer distance than controls at 29 days
post-injury (P < .05). There were no differences in distance traveled between the control
group and the combined riluzole and MgSO4 group.
 There were no significant differences in swimming velocities between the riluzole and
control groups.
Wu et al (2013)19  Rats treated with riluzole (8 mg/kg 1 and 3 hours after injury) achieved significantly higher
BBB scores than controls at 2 to 6 weeks after injury (P < .05).
(continued)
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indicated that riluzole given before ischemia is more effective
than riluzole injected at the onset of reperfusion.10
Gait Analysis and Grip Strength. Gait analysis was performed in 4
studies.19,26,28,33 Compared with controls, riluzole resulted in
significantly shorter limb swing phases; greater paw pressure;
longer ipsilateral stride length, print width during stance phase
and print length; reduced number of footfalls; and a higher
percentage of ipsilateral paw placements.19,26,28 Print length
and width of the contralateral forepaw, however, did not sig-
nificantly differ between riluzole and control groups.28 In a
study by Karadimas et al, a combination of surgical decom-
pression and riluzole resulted in longer forelimb stride length,
higher regularity index, shorter forepaw initial contact, shorter
stance phase, stronger hand grip, and decreased print positions
than decompression alone.33 Finally, ipsilateral and contralat-
eral grip strength were significantly higher in rats treated with
riluzole than controls.28
Inclined Plane Scores. Three studies assessed the association
between riluzole and inclined plane scores.9,22,29 In a study
by Schwartz and Fehlings, rats treated with riluzole exhibited
higher inclined plane scores than controls at 1 to 4 and 6 weeks
following injury.29 This positive finding was confirmed by
Ates et al.9 In contrast, the study by Hosier et al did not detect
significant differences in inclined plane scores between the
control and riluzole groups in a model of unilateral cervical
SCI.22
Other Measures. Based on single studies, rats receiving riluzole
exhibited significantly longer time on accelerating rotarod,
improved motor sensory deficit index, and a longer distance
traveled on an activity test than controls.22,25,30 Furthermore, a
study by Kitzman demonstrated that rats receiving 10 mg/kg of
riluzole had a significantly decreased response to light touch,
stretch, and pinch compared with controls at 1 and 3 hours, but
not at 6 and 12 hours, post injection.24 In contrast, single
studies identified no association between treatment with rilu-
zole and beam balance scores or swimming velocities.22,30
Discussion
This systematic review aims to evaluate the association
between riluzole and neurobehavioral outcomes in preclinical
models of traumatic and nontraumatic SCI. Based on the
results, riluzole has a significant impact on locomotor scores,
gait parameters, and measures of hyperalgesia and mechanical
allodynia.
The most common outcome assessment tool used across
studies was the BBB locomotor score, which was originally
designed to evaluate midline thoracic injuries.22 Other tests
were also conducted to assess upper extremity function in iso-
lation as well as coordination of the forelimbs and hindlimbs;
these included grip strength, accelerating rotarod, and beam
balance.22,28 As summarized by this review, riluzole signifi-
cantly improved motor recovery, locomotion, and functional
outcomes in a variety of animal models of traumatic and non-
traumatic SCI. Potential explanations for these results include
(1) sparing of serotonergic and glutamatergic fibers involved in
maintaining posture, initiating locomotion, and/or modulating
neuronal circuits and (2) increased neuron counts in the red,
reticular, and vestibular nuclei.29,30 In contrast, a study by
Vasconcelos et al reported that riluzole did not affect swim-
ming velocities; this is likely because swimming does not
require body weight support due to buoyancy.30 Furthermore,
some studies indicated that riluzole does not have an impact on
BBB locomotor score, upper extremity function, or coordina-
tion.12,22,27,29 Timing and duration of riluzole administration
may also be a relevant consideration; specifically, rapid and
prolonged treatment enables immediate and continued block-
age of glutamatergic excitotoxicity and improved neurobeha-
vioral outcomes.11,19
This review also indicated that riluzole may attenuate neu-
ropathic pain and suppress spasticity. Injury to the spinal cord
Table 5. (continued)
Author (Year) Statistical Analysis Main Conclusions
 One-way or 2-way
ANOVA with repeated
measures with post hoc
Bonferroni test
 Rats treated with riluzole (8 mg/kg at 1 but not 3 hours after injury) achieved significantly
higher BBB subscores than controls (P < .01).
 Rats treated with riluzole (8 mg/kg at 1 but not 3 hours after injury) demonstrated a
significantly reduced number of footfalls at 3 to 6 weeks post-injury than controls (P <
.05).
 There were no significant differences in withdrawal threshold between riluzole and
control groups.
Wu et al (2014)31  Two-way ANOVA with
repeated measures and
post hoc Bonferroni
test
 Rats treated with riluzole achieved significantly higher BBB scores (1 and 5 days post-
ischemia) and coordination and stepping subscores (4 hours, 1 and 5 days post-ischemia)
than controls (P < .001).
Abbreviations: SCI, spinal cord injury; i.p., intraperitoneally; i.v., intravenously; i.c.v., intracerebroventricularly; i.t., intrathecally; BBB, Basso, Beattie, Besnahan;
MSDI, Motor Sensory Deficit Index; ANOVA, analysis of variance.
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results in hyperalgesia and mechanical allodynia below the
level of injury while increasing spontaneous activity at the
dorsal horn.12,26 These findings were confirmed by increased
withdrawal thresholds to innocuous stimuli and an increase in
tail flick latency following application of a radiant heat sti-
muli.12,26 Moreover, there was a significant decrease in
response to noxious and non-noxious stimuli, including stretch,
pinch, and light touch.24 Riluzole affects these outcomes by
modulating glutamatergic excitotoxicity in the dorsal horn.26
Furthermore, an increase in spontaneous activity may be due to
a decrease in inhibitory GABAergic interneurons at the dorsal
horn as well as a reduction of descending inhibition from the
bulbospinal serotonergic and adrenergic neurons.12 Longer
term changes may also occur, including increased gene tran-
scription of voltage gated sodium channels, causing abnormal
physiological responses to peripheral stimulation. Finally, the
administration dose may be an important consideration as
lower doses of riluzole (eg, 0.8 or 2.5 mg/kg) do not improve
sensitivity to innocuous mechanical stimuli.12 The dose
response gradient observed on intracerebroventricular injection
of riluzole signifies that the brain (in addition to the peripheral
nerves) may also be a key site of riluzole’s actions; specifically,
it is hypothesized that the ventral posterolateral nucleus of the
thalamus may be an important target.12
Riluzole may also significantly improve gait parameters. In
a study by Karadimas et al, surgical decompression was asso-
ciated with increased blood flow and reperfusion of the spinal
cord parenchyma.33 Reperfusion of the gray matter resulted in
chronic and persistent neuronal oxidative damage as well as
increased expression of DNA damage repair processes.33 This
study also demonstrated that riluzole can attenuate ischemia
reperfusion injury associated with decompression surgery,
decrease oxidative damage, and protect against destruction of
the mitochondrial membrane. Furthermore, a combination of
surgical decompression and riluzole can significantly improve
forelimb function and nearly restore a smooth and rhythmic
gait pattern.33 In addition to restoration of motor function,
improvement in gait parameters may also reflect a reduction
in sensitivity to mechanical stimulation. In a study by Moon
et al, rats treated with riluzole had significantly longer contact
between the paw and the glass plate.26
This review provides the background information necessary
to interpret the results of clinical trials on the impact of riluzole
in traumatic and nontraumatic SCI. Improvements in tissue
damage and neurobehavioral outcomes may significantly affect
quality of life in these patients.
Strengths and Limitations
This systematic review reflects the first to evaluate the impact of
riluzole on neurobehavioral outcomes in preclinical models of
traumatic and nontraumatic SCI. Strengths of this review include
the following: (1) the search strategy was extensive, (2) 2
reviewers independently evaluated the articles for eligibility,
(3) the evidence was assessed using the SYRCLE tool, and (4)
the review was formatted using the PRISMA guidelines.
Limitations of this review include the following: (1) studies were
excluded if they were not in English and (2) it was challenging to
assess certain domains of the SYRCLE tool.
Conclusion
In preclinical models of traumatic and nontraumatic SCI, rilu-
zole significantly improves locomotor scores, gait function,
and measures of neuropathic pain. This review provides the
background information necessary to interpret the results of
clinical trials on the impact of riluzole in traumatic and non-
traumatic SCI.
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